Gene Expression and miRNAs Profiling: Function and Regulation in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer.
Rasha M SareyeldinIshita GuptaIsraa Al-HashimiHamda A Al-ThawadiHalema F Al FarsiSemir VranicAla-Eddin Al MoustafaPublished in: Cancers (2019)
Breast cancer is the second most common cause of cancer-related deaths among women worldwide. It is a heterogeneous disease with four major molecular subtypes. One of the subtypes, human epidermal growth factor receptor 2 (HER2)-enriched (HER2-positive) is characterized by the absence of estrogen and progesterone receptors and overexpression of HER2 receptor, and accounts for 15-20% of all breast cancers. Despite the anti-HER2 and cytotoxic chemotherapy, HER2 subtype is an aggressive disease with significant mortality. Recent advances in molecular biology techniques, including gene expression profiling, proteomics, and microRNA analysis, have been extensively used to explore the underlying mechanisms behind human breast carcinogenesis and metastasis including HER2-positive breast cancer, paving the way for developing new targeted therapies. This review focuses on recent advances on gene expression and miRNA status in HER2-positive breast cancer.
Keyphrases
- positive breast cancer
- epidermal growth factor receptor
- gene expression
- endothelial cells
- tyrosine kinase
- advanced non small cell lung cancer
- induced pluripotent stem cells
- pluripotent stem cells
- dna methylation
- cardiovascular disease
- squamous cell carcinoma
- mass spectrometry
- cell proliferation
- insulin resistance
- estrogen receptor
- polycystic ovary syndrome
- cardiovascular events
- transcription factor
- single molecule
- skeletal muscle
- metabolic syndrome
- copy number
- genome wide identification
- rectal cancer